| Nome |
# |
|
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma, file e27ce42a-e94a-2581-e053-d805fe0acbaa
|
525
|
|
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma, file e27ce428-83bb-2581-e053-d805fe0acbaa
|
446
|
|
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study., file e27ce427-a38f-2581-e053-d805fe0acbaa
|
307
|
|
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients, file e27ce42a-ee98-2581-e053-d805fe0acbaa
|
222
|
|
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma, file e27ce430-af99-2581-e053-d805fe0acbaa
|
213
|
|
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study, file e27ce435-83b6-2581-e053-d805fe0acbaa
|
192
|
|
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study, file e27ce427-7c64-2581-e053-d805fe0acbaa
|
157
|
|
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis, file e27ce42f-8645-2581-e053-d805fe0acbaa
|
152
|
|
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups, file e27ce427-8421-2581-e053-d805fe0acbaa
|
150
|
|
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, file e27ce42f-8b46-2581-e053-d805fe0acbaa
|
140
|
|
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma, file e27ce42c-91d4-2581-e053-d805fe0acbaa
|
137
|
|
Emerging drugs and combinations to treat multiple myeloma, file e27ce430-f3b6-2581-e053-d805fe0acbaa
|
117
|
|
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, file e27ce427-76e7-2581-e053-d805fe0acbaa
|
96
|
|
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA), file e27ce42d-5d05-2581-e053-d805fe0acbaa
|
92
|
|
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, file e27ce431-3459-2581-e053-d805fe0acbaa
|
90
|
|
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report, file e27ce427-b676-2581-e053-d805fe0acbaa
|
85
|
|
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN), file e27ce435-99a2-2581-e053-d805fe0acbaa
|
83
|
|
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma, file e27ce430-925f-2581-e053-d805fe0acbaa
|
70
|
|
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study., file e27ce427-e241-2581-e053-d805fe0acbaa
|
58
|
|
Monoclonal antibodies to treat multiple myeloma: A dream come true, file e27ce431-d5bc-2581-e053-d805fe0acbaa
|
55
|
|
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma, file 185097a3-5f0f-4eca-ba69-26ed618f2ebd
|
49
|
|
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis, file e27ce435-863a-2581-e053-d805fe0acbaa
|
49
|
|
Multiple myeloma patients undergoing carfilzomib: Development and validation of a risk score for cardiovascular adverse events prediction, file e27ce431-dbd0-2581-e053-d805fe0acbaa
|
48
|
|
The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma, file e27ce432-06fe-2581-e053-d805fe0acbaa
|
43
|
|
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score, file e27ce431-d76d-2581-e053-d805fe0acbaa
|
42
|
|
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma, file e27ce431-52f2-2581-e053-d805fe0acbaa
|
41
|
|
Treatment of newly diagnosed elderly multiple myeloma, file e27ce435-7ca7-2581-e053-d805fe0acbaa
|
37
|
|
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension, file a80eb078-016b-45f2-b47c-8f0139cbeb1c
|
34
|
|
Determining treatment intensity in elderly patients with multiple myeloma, file e27ce435-9705-2581-e053-d805fe0acbaa
|
31
|
|
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients, file e27ce431-df1e-2581-e053-d805fe0acbaa
|
29
|
|
Ultra-Low-Dose Whole-Body Computed Tomography Protocol Optimization for Patients With Plasma Cell Disorders: Diagnostic Accuracy and Effective Dose Analysis From a Reference Center, file e27ce434-dfdd-2581-e053-d805fe0acbaa
|
29
|
|
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial, file e27ce432-1245-2581-e053-d805fe0acbaa
|
28
|
|
How is patient care for multiple myeloma advancing?, file e27ce435-a035-2581-e053-d805fe0acbaa
|
26
|
|
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma, file e27ce42c-9e99-2581-e053-d805fe0acbaa
|
25
|
|
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma, file 489a1238-a926-41d6-a0aa-7120055380bb
|
16
|
|
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, file e27ce432-5582-2581-e053-d805fe0acbaa
|
16
|
|
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial, file e27ce434-dda5-2581-e053-d805fe0acbaa
|
16
|
|
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file e27ce435-6515-2581-e053-d805fe0acbaa
|
14
|
|
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials, file e27ce435-88a9-2581-e053-d805fe0acbaa
|
14
|
|
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies, file e27ce435-4d75-2581-e053-d805fe0acbaa
|
13
|
|
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file a4e97a93-3d82-4aaa-b92d-85fef843542e
|
12
|
|
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma, file e27ce435-2fcf-2581-e053-d805fe0acbaa
|
12
|
|
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial, file e27ce435-83f3-2581-e053-d805fe0acbaa
|
12
|
|
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, file e27ce428-a199-2581-e053-d805fe0acbaa
|
11
|
|
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials, file e27ce431-2e53-2581-e053-d805fe0acbaa
|
11
|
|
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma, file e27ce435-8204-2581-e053-d805fe0acbaa
|
11
|
|
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma, file e27ce435-4081-2581-e053-d805fe0acbaa
|
10
|
|
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials, file e27ce435-516c-2581-e053-d805fe0acbaa
|
10
|
|
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file e27ce431-1142-2581-e053-d805fe0acbaa
|
7
|
|
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma, file 37a6a934-f6f7-48fb-943b-31968b6436ec
|
5
|
|
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma, file e27ce432-2dad-2581-e053-d805fe0acbaa
|
5
|
|
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma, file e27ce435-4969-2581-e053-d805fe0acbaa
|
5
|
|
Treatment of newly diagnosed elderly multiple myeloma, file e27ce435-7b03-2581-e053-d805fe0acbaa
|
5
|
|
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma, file e27ce435-852f-2581-e053-d805fe0acbaa
|
5
|
|
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma, file e27ce431-17eb-2581-e053-d805fe0acbaa
|
4
|
|
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study, file e27ce435-5623-2581-e053-d805fe0acbaa
|
4
|
|
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma, file e27ce435-602e-2581-e053-d805fe0acbaa
|
4
|
|
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients., file e27ce435-7f6c-2581-e053-d805fe0acbaa
|
4
|
|
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review, file f50cdee7-b492-428c-9d8c-bc18fb5b65ed
|
4
|
|
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia., file e27ce430-d1fc-2581-e053-d805fe0acbaa
|
3
|
|
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma, file e27ce431-d75d-2581-e053-d805fe0acbaa
|
3
|
|
Melphalan and its role in the management of patients with multiple myeloma, file e27ce431-e0d0-2581-e053-d805fe0acbaa
|
3
|
|
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study., file e27ce435-407b-2581-e053-d805fe0acbaa
|
3
|
|
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension, file e27ce435-889d-2581-e053-d805fe0acbaa
|
3
|
|
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies, file 52f0f584-8fc9-4d40-b3a7-b5b1fd8b1d9a
|
2
|
|
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma, file 5c9d2b60-09e0-49eb-9c2c-ee2f867045f5
|
2
|
|
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival., file 7876b7fe-744b-406a-b066-f42213a05937
|
2
|
|
Approach to the Older Adult With Multiple Myeloma, file e27ce42f-6c47-2581-e053-d805fe0acbaa
|
2
|
|
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN), file e27ce431-da1d-2581-e053-d805fe0acbaa
|
2
|
|
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report, file e27ce432-5da3-2581-e053-d805fe0acbaa
|
2
|
|
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival., file e27ce435-2e47-2581-e053-d805fe0acbaa
|
2
|
|
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients., file e27ce435-7965-2581-e053-d805fe0acbaa
|
2
|
|
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma, file e27ce435-813e-2581-e053-d805fe0acbaa
|
2
|
|
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials, file e27ce435-a4cd-2581-e053-d805fe0acbaa
|
2
|
|
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma, file 0535c2ac-4a44-4200-b69d-f7ea162511a0
|
1
|
|
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension, file 2acccf7c-84a6-44fd-b2c8-acb3c9edbe06
|
1
|
|
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients, file 511a3b81-6d68-4c62-b08c-c0671d9e6604
|
1
|
|
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma, file 83fd1b50-5e9e-43f2-b97b-386e3da945b1
|
1
|
|
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients, file 9a9ba6f8-e801-4727-8992-21f9a950f3fc
|
1
|
|
Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis, file e27ce42f-4889-2581-e053-d805fe0acbaa
|
1
|
|
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy, file e27ce42f-5414-2581-e053-d805fe0acbaa
|
1
|
|
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma, file e27ce431-3078-2581-e053-d805fe0acbaa
|
1
|
|
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma, file e27ce432-5f85-2581-e053-d805fe0acbaa
|
1
|
|
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma, file e27ce435-a357-2581-e053-d805fe0acbaa
|
1
|
|
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients, file f34301c1-813b-4257-959b-74733bc7db02
|
1
|
| Totale |
4.174 |